The United States Patent and Trademark Office (USPTO) has issued a patent entitled, Abuse-Resistant Oral Dosage Forms and Method of Use Thereof, to Elite Pharmaceuticals. The patent will protect the Elite's proprietary formulation for ...
BioDelivery Sciences International (BDSI) announced that the USPTO has granted BDSI's patent which extends the patent protection for BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, by seven ...
Lixte Biotechnology, a cancer drug discovery company, has received a notice of allowance from the USPTO for its histone deacetylase inhibitor (HDACi), LB-201, and other structural homologs. Lixte founder and president John Kovach said ...
Tags: USPTO, cancer treatment, clinical technology, pharmaceutical product